VLVelimir Luketic

Velimir Luketic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Velimir Luketic has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis

    by Anish Reddy, Adrielly Martins, Christopher L. Bowlus, Marlyn J. Mayo, Elizabeth J. Carey, Mark Wong, Michael Weiss, Hany Elbeshbeshy, Raymond Rubin, Velimir Luketic, et al.

    INTRODUCTION: Despite the widespread use of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC), many patients remain at risk of progression. Emerging data suggest that normalization of alkaline phosphatase (ALP) and total bilirubin (TB)—particularly when TB < 0.6 times the upper limit of normal (× ULN)—is associated with improved outcomes compared with ALP reduction to < 1.5 × ULN. This study investigated the association between ALP normalization in response to UDCA and long-term clinical outcomes in a real-world cohort of patients with PBC. METHODS: We compared complication-free survival in patients achieving an ALP > ULN and < 1.5 × ULN (adequate response) with those with an ALP ≤ ULN on UDCA monotherapy. Complication-free survival was defined as the absence of serious liver-related clinical events. Restricted mean survival time was used to quantify survival time gained. RESULTS: Patients achieving normal ALP and/or TB ≤ 0.6 × ULN demonstrated significantly improved complication-free survival compared with those with an adequate ALP response. Event-free survival was extended by 1.34 years (95% CI: 0.56, 2.11; P = 0.001) for ALP normalization alone, 3.7 years (95% CI: 3.11, 4.29; P < 0.001) for TB ≤ 0.6 × ULN, and 4.51 years (95% CI: 4.13, 4.88; P < 0.001) for those meeting both criteria. The risk of severe clinical events was reduced in patients achieving ALP normalization (hazard ratio [HR] 0.34; 95% CI: 0.15, 0.80; P = 0.01), TB ≤ 0.6 × ULN (HR 0.23; 95% CI: 0.09, 0.55; P = 0.001), or both (HR 0.14; 95% CI: 0.05, 0.38; P < 0.001). High-risk patients, defined by liver stiffness measurement ≥ 10 kPa or clinical, histological, or laboratory evidence of cirrhosis or portal hypertension, derived the greatest benefit. DISCUSSION: Achieving normal ALP and TB ≤ 0.6 × ULN is associated with significantly improved complication-free survival, particularly in high-risk patients. These findings highlight the potential of biochemical thresholds as a meaningful therapeutic goal in PBC management.


  • Open Access

    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial

    by Cynthia Levy, George F. Abouda, Bahri M. Bilir, Alan Bonder, Christopher L. Bowlus, Isabel Campos-Varela, Nora Cazzagon, Natasha Chandok, Kuldeep Cheent, Helena Cortez-Pinto, et al.


  • A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study

    by Andrew Fagan, Edith A. Gavis, Mary Leslie Gallagher, Travis Mousel, Brian Davis, Puneet Puri, Richard K. Sterling, Velimir A. Luketic, Hannah Lee, Scott C. Matherly, et al.


  • Open Access

    Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4

    by Bubu A. Banini, Samarth Patel, Jonathan W. Ma Yu, Le Kang, Christopher Do Bailey, Brian J. Strife, Mohammad S. Siddiqui, Vaishali Patel, Scott C. Matherly, Hannah Lee, et al.

    Background: Liver biopsy and hepatic venous pressure gradient (HVPG), the gold standard for assessing advanced fibrosis (AF) and clinically significant portal hypertension (CSPH), are invasive, costly, and time-consuming. Goal: We investigated if the combination of fibrosis index based on 4 factors (FIB-4) and liver stiffness measure (LSM) can identify AF and more importantly, CSPH. Patients and Methods: Patients with chronic liver disease referred for transjugular liver biopsy were analyzed retrospectively. FIB-4 and LSM were compared with liver histology for diagnosing AF. FIB-4, LSM, and platelet count were compared with HVPG for diagnosing CSPH. Optimal cutoffs for predicting CSPH were determined by grid search. A composite log-odds to predict CSPH was derived from logistic regression using LSM, FIB-4, and gender. Internal bootstrap validation and external validation were performed. Results: A total of 142 patients were included in the derivation; 42.3% had AF, and 11.3% had CSPH using the current gold standards. The area under the receiver operating characteristic curve (AUROC) for LSM, FIB-4, and their combination to predict AF were 0.7550, 0.7049, and 0.7768, respectively. LSM, FIB-4, and platelet count predicted CSPH with AUROC 0.6818, 0.7532, and 0.7240, respectively. LSM plus FIB-4 showed the best performance in predicting CSPH with AUROC 0.8155. Based on LSM, FIB-4, and gender, a novel model—the Portal Hypertension Assessment Tool (PHAT)—was developed to predict CSPH. PHAT score ≥−2.76 predicted CSPH with sensitivity 94%, specificity 67%, positive predictive value 27%, negative predictive value 99%, and accuracy 70%. In internal and external validation, AUROCs for the model were 0.8293 and 0.7899, respectively. Conclusion: A model consisting of FIB-4, LSM, and gender can identify CSPH among patients with chronic liver disease.


  • Top Cited Papers
    Open Access

    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

    by Jörn M. Schattenberg, Albert Pares, Kris V. Kowdley, Michael A. Heneghan, Stephen Caldwell, Daniel Pratt, Alan Bonder, Gideon M. Hirschfield, Cynthia Levy, John Vierling, et al.


  • Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review.

    by A M Freedman, A J Sanyal, J Tisnado, P E Cole, M L Shiffman, V A Luketic, P P Purdum, M D Darcy, M P Posner

    It is generally accepted that the transjugular intrahepatic portosystemic shunt (TIPS) procedure has lower morbidity and mortality rates than those of surgical shunting. Nevertheless, complications occur. The authors have reviewed their experience and that of other institutions in compiling an extensive list of complications. Complications are categorized according to those related to transhepatic needle puncture, transvenous access to the portal vein, portal venous cannulation, the stent, the puncture site, portosystemic shunting, and contrast material. Excluding hepatic encephalopathy and delayed stenosis or occlusion of the shunt, an overall complication rate of less than 10% can be expected for TIPS. The prevalence of aggravated or new cases of encephalopathy is 5%-35%, and over the long term, up to 75% of shunts may undergo stenosis or occlusion. The direct procedural mortality rate is less than 2%, and the 30-day mortality rate ranges from 4% to 45%, depending on several factors. The role to which TIPS is relegated will be influenced by the long-term success rate in the prevention of recurrent variceal hemorrhage.